Cookies on this site

Oxford scientists are part of a new £15.9 million UK initiative to transform disease research through the development of advanced human tissue models. The INTREPID project will evaluate and optimise the use of live human tumour samples to enhance the accuracy of preclinical research, speed up drug discovery, and reduce dependence on animal testing.

Watching some samples through a microscope

A major new initiative involving Oxford experts aims to redefine human-based research models to improve understanding of disease and accelerate the development of new medicines. 

The joint £15.9 million investment by the Medical Research Council (MRC), Wellcome Trust, and Innovate UK will enable the development of advanced, specific, and highly reproducible human in vitro models, with the aim of making them widely available to researchers in academia and industry.

In vitro models use isolated cells and tissues outside the living body and can take many forms, including stem-cell derived aggregates that display organ-like features on a smaller scale (organoids), tissue slices removed during surgery (called explant or ex vivo cultures); and organ-on-chips, small devices that use tiny channels to pass fluids through living cells, mimicking how organs work inside the body. The development of accurate and physiologically relevant in vitro models for studying disease biology and drug development aims to improve the translatability of research, while reducing reliance on animal models.

A coordinated network of five interdisciplinary teams will focus on the development of in vitro disease models of the liver, brain, cancer, pain and blood vessels.

Eric O’Neill, Professor of Cell and Molecular Biology, Department of Oncology, is part of the INTREPID project (IN vitro TumouR Explant models for evaluating cancer complexity and Patient Diversity) project, which aims to tackle the barriers associated with widespread adoption of live human tumour tissue explant models – to drive  progress in their use in cancer research.

 

Read the full story on the the Department of Oncology website.

 

Similar stories

Research shows for the first time that standard non-contrast CT scans can be analysed by AI to reveal hidden coronary inflammation

Researchers from 27 institutions across UK, USA, Europe and Australia, led by a team at the University of Oxford, have demonstrated how an AI technology can measure inflammation in the heart’s arteries using low-radiation CT heart scans typically used to measure calcium score.

Five European Research Council (ERC) Synergy Grants awarded to Oxford researchers for ambitious new collaborations

Five Oxford University academics are to co-lead ambitious new research projects backed by European Research Council (ERC) Synergy Grants, part of the EU’s Horizon Europe research and innovation programme. Synergy Grants support groups of two to four outstanding researchers who combine complementary expertise and resources to tackle ambitious scientific challenges that could not be addressed by individual teams alone.

Professor Ole Jensen (Department of Experimental Psychology) and colleagues received €13.6 million to discover when the brain is ready for language and social understanding

The team will use new wearable brain sensors to track cognitive development from before birth to eight years of age.

New 'molecular glue' helps break down antibiotic resistance enzymes in E. coli

Oxford University scientists have discovered a new approach to tackle antimicrobial resistance (AMR), using 'molecular glues' to encourage bacteria to destroy their own resistance-causing enzymes. The study has been published in Angewandte Chemie International Edition.

Stronger immune system may help protect against prostate cancer

Higher levels of proteins involved in activating and coordinating the immune system were associated with a lower risk of developing prostate cancer, in a new study led by researchers at the Nuffield Department of Population Health.

The Nuffield Department of Women's & Reproductive Health has published its Biennial Report 2024–26

The Biennial Report 2024–26 highlights two years of research excellence, innovation, collaboration and growth.